USNA PE Ratio & Valuation,Is USNA Overvalued

USNA Relative Valuation

USNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, USNA is overvalued; if below, it's undervalued.

Historical Valuation

USANA Health Sciences Inc (USNA) is now in the Undervalued zone, suggesting that its current forward PE ratio of 11.17 is considered Undervalued compared with the five-year average of 17.42. The fair price of USANA Health Sciences Inc (USNA) is between 25.98 to 37.61 according to relative valuation methord. Compared to the current price of 19.57 USD , USANA Health Sciences Inc is Undervalued By 24.68%.

Relative Value

Fair Zone

25.98-37.61

Current Price：19.57

24.68%

Undervalued

11.17

2.56

EV/EBITDA

USANA Health Sciences Inc. (USNA) has a current EV/EBITDA of 2.56. The 5-year average EV/EBITDA is 6.73. The thresholds are as follows: Strongly Undervalued below 1.51, Undervalued between 1.51 and 4.12, Fairly Valued between 9.34 and 4.12, Overvalued between 9.34 and 11.95, and Strongly Overvalued above 11.95. The current Forward EV/EBITDA of 2.56 falls within the Undervalued range.

6.25

EV/EBIT

USANA Health Sciences Inc. (USNA) has a current EV/EBIT of 6.25. The 5-year average EV/EBIT is 9.07. The thresholds are as follows: Strongly Undervalued below 3.69, Undervalued between 3.69 and 6.38, Fairly Valued between 11.76 and 6.38, Overvalued between 11.76 and 14.45, and Strongly Overvalued above 14.45. The current Forward EV/EBIT of 6.25 falls within the Undervalued range.

0.40

USANA Health Sciences Inc. (USNA) has a current PS of 0.40. The 5-year average PS is 1.16. The thresholds are as follows: Strongly Undervalued below 0.33, Undervalued between 0.33 and 0.75, Fairly Valued between 1.57 and 0.75, Overvalued between 1.57 and 1.98, and Strongly Overvalued above 1.98. The current Forward PS of 0.40 falls within the Undervalued range.

6.28

P/OCF

USANA Health Sciences Inc. (USNA) has a current P/OCF of 6.28. The 5-year average P/OCF is 11.73. The thresholds are as follows: Strongly Undervalued below 2.25, Undervalued between 2.25 and 6.99, Fairly Valued between 16.47 and 6.99, Overvalued between 16.47 and 21.21, and Strongly Overvalued above 21.21. The current Forward P/OCF of 6.28 falls within the Undervalued range.

8.59

P/FCF

USANA Health Sciences Inc. (USNA) has a current P/FCF of 8.59. The 5-year average P/FCF is 13.29. The thresholds are as follows: Strongly Undervalued below -3.17, Undervalued between -3.17 and 5.06, Fairly Valued between 21.52 and 5.06, Overvalued between 21.52 and 29.75, and Strongly Overvalued above 29.75. The current Forward P/FCF of 8.59 falls within the Historic Trend Line -Fairly Valued range.

USANA Health Sciences Inc (USNA) has a current Price-to-Book (P/B) ratio of 0.67. Compared to its 3-year average P/B ratio of 1.69 , the current P/B ratio is approximately -60.29% higher. Relative to its 5-year average P/B ratio of 2.66, the current P/B ratio is about -74.67% higher. USANA Health Sciences Inc (USNA) has a Forward Free Cash Flow (FCF) yield of approximately 5.26%. Compared to its 3-year average FCF yield of 7.25%, the current FCF yield is approximately -27.48% lower. Relative to its 5-year average FCF yield of 7.20% , the current FCF yield is about -26.95% lower.

0.67

P/B

Median3y

1.69

Median5y

2.66

5.26

FCF Yield

Median3y

7.25

Median5y

7.20

Competitors Valuation Multiple

The average P/S ratio for USNA's competitors is 1.55, providing a benchmark for relative valuation. USANA Health Sciences Inc Corp (USNA) exhibits a P/S ratio of 0.40, which is -74.45% above the industry average. Given its robust revenue growth of 6.72%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of USNA decreased by 39.91% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 10.19 to 21.63.

The secondary factor is the Revenue Growth, contributed 6.72%to the performance.

Overall, the performance of USNA in the past 1 year is driven by P/E Change. Which is more unsustainable.

6.72%

200.22M → 213.67M

Revenue Growth

-158.87%

5.30 → -3.12

Margin Expansion

112.24%

10.19 → 21.63

P/E Change

-39.91%

32.57 → 19.57

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is USANA Health Sciences Inc (USNA) currently overvalued or undervalued?

What is USANA Health Sciences Inc (USNA) fair value?

USNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of USANA Health Sciences Inc (USNA) is between 25.98 to 37.61 according to relative valuation methord.

How does USNA's valuation metrics compare to the industry average?

What is the current P/B ratio for USANA Health Sciences Inc (USNA) as of Jan 08 2026?

As of Jan 08 2026, USANA Health Sciences Inc (USNA) has a P/B ratio of 0.67. This indicates that the market values USNA at 0.67 times its book value.

What is the current FCF Yield for USANA Health Sciences Inc (USNA) as of Jan 08 2026?

As of Jan 08 2026, USANA Health Sciences Inc (USNA) has a FCF Yield of 5.26%. This means that for every dollar of USANA Health Sciences Inc’s market capitalization, the company generates 5.26 cents in free cash flow.

What is the current Forward P/E ratio for USANA Health Sciences Inc (USNA) as of Jan 08 2026?

As of Jan 08 2026, USANA Health Sciences Inc (USNA) has a Forward P/E ratio of 11.17. This means the market is willing to pay $11.17 for every dollar of USANA Health Sciences Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for USANA Health Sciences Inc (USNA) as of Jan 08 2026?

As of Jan 08 2026, USANA Health Sciences Inc (USNA) has a Forward P/S ratio of 0.40. This means the market is valuing USNA at $0.40 for every dollar of expected revenue over the next 12 months.

USNA Valuation